Researcher
Oliver Bechter
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Oncology (Division)
Member
From7 May 2012 → Today
Projects
1 - 5 of 5
- Dissecting the heterotypic cell communication networks at the perivascular niche to detect andintercept the early metastatic processFrom1 Jan 2023 → TodayFunding: BOF - iBOF
- Multiplexed immunohistochemistry and digital pathology as the foundation for next-generation pathology in melanoma researchFrom1 Oct 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Next-generation pathology by MILAN: multiplex immunohistochemistry and advanced trainable image analysisFrom1 Jan 2020 → 31 Dec 2021Funding: IOF - technology validation in lab
- Preventing therapy-induced cancer stemnessFrom1 Oct 2019 → TodayFunding: IOF - technology concept exploration, BOF - projects
- Treating melanoma as an infectious diseaseFrom1 Sep 2018 → 31 Aug 2022Funding: Foundations, funds and other with scientific goal
Publications
21 - 30 of 81
- Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer(2022)
Authors: Ward Celus, Silvia Rivis, Ewout Landeloos, Yannick Van Herck, Abhishek Garg, Chris Marine, Mario di Matteo, Oliver Bechter, Max Mazzone
Pages: 126 - 141 - Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data(2021)
Authors: Oliver Bechter
Pages: 5098 - 5106 - Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East(2021)
Authors: Oliver Bechter
Pages: 1926 - 1934 - Road to Metastasis: The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick Melanomas(2021)
Authors: Canan Guvenc, Veerle Boecxstaens, Oliver Bechter, Jurgen Vercauteren, Maria Garmyn, Joost van den Oord, Francesca Bosisio
- Is cancer biology different in older patients?(2021)
Authors: Yannick Van Herck, Yentl Lambrechts, Oliver Bechter, Christine Desmedt, Sigrid Hatse, Hans Wildiers
Pages: E663 - E677 - Activation of the integrated stress response confers vulnerability to mitoribosome-targeting antibiotics in melanoma(2021)
Authors: Vicky Katopodi, Sonia Cinque, Zorica Knezevic, Sara Adnane, Yvessa Verheyden, Panagiotis Karras, Francesca Bosisio, Oliver Bechter, Chris Marine, Eleonora Leucci
- Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors.(2021)
Authors: Lisa Kinget, Oliver Bechter, Kevin Punie, Hilde Brems, Paul Clement, Eduard Roussel, Yannick Van Herck, Maarten Albersen, Marcella Baldewijns, Patrick Schöffski, et al.
Pages: 3227 - 3239 - Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma(2021)
Authors: Michael Dewaele, Panagiotis Karras, Nina Van Raemdonck, Dennis Pedri, Jonas Demeulemeester, Sara Vander Borght, Francesca Bosisio, Joost van den Oord, Isabelle Vanden Bempt, Diether Lambrechts, et al.
Pages: 1135 - + - Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial(2021)
Authors: Oliver Bechter
Pages: 848 - 857 - Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy(2021)
Authors: Isaure Vanmeerbeek, Daniel Borras Morales, Jenny Sprooten, Oliver Bechter, Sabine Tejpar, Abhishek Garg
Pages: 108 - 119